Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Bone marrow therapy for myocardial infarction.

Literature DB >> 22084194

Bone marrow therapy for myocardial infarction.

Joshua M Hare.

Abstract

Entities: Chemical Disease Gene Species

Mesh：

Year: 2011 PMID： 22084194 PMCID： PMC4745991 DOI： 10.1001/jama.2011.1686

Source DB: PubMed Journal: JAMA ISSN： 0098-7484 Impact factor: 56.272

× No keyword cloud information.

15 in total

1. Autologous mesenchymal stem cells mobilize cKit+ and CD133+ bone marrow progenitor cells and improve regional function in hibernating myocardium.

Authors: Gen Suzuki; Vijay Iyer; Te-Chung Lee; John M Canty
Journal: Circ Res Date: 2011-09-01 Impact factor: 17.367

2. Bone marrow mesenchymal stem cells stimulate cardiac stem cell proliferation and differentiation.

Authors: Konstantinos E Hatzistergos; Henry Quevedo; Behzad N Oskouei; Qinghua Hu; Gary S Feigenbaum; Irene S Margitich; Ramesh Mazhari; Andrew J Boyle; Juan P Zambrano; Jose E Rodriguez; Raul Dulce; Pradip M Pattany; David Valdes; Concepcion Revilla; Alan W Heldman; Ian McNiece; Joshua M Hare
Journal: Circ Res Date: 2010-07-29 Impact factor: 17.367

3. Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction.

Authors: Volker Schächinger; Sandra Erbs; Albrecht Elsässer; Werner Haberbosch; Rainer Hambrecht; Hans Hölschermann; Jiangtao Yu; Roberto Corti; Detlef G Mathey; Christian W Hamm; Tim Süselbeck; Birgit Assmus; Torsten Tonn; Stefanie Dimmeler; Andreas M Zeiher
Journal: N Engl J Med Date: 2006-09-21 Impact factor: 91.245

Review 4. Mesenchymal stem cells: biology, pathophysiology, translational findings, and therapeutic implications for cardiac disease.

Authors: Adam R Williams; Joshua M Hare
Journal: Circ Res Date: 2011-09-30 Impact factor: 17.367

5. Intramyocardial stem cell injection in patients with ischemic cardiomyopathy: functional recovery and reverse remodeling.

Authors: Adam R Williams; Barry Trachtenberg; Darcy L Velazquez; Ian McNiece; Peter Altman; Didier Rouy; Adam M Mendizabal; Pradip M Pattany; Gustavo A Lopera; Joel Fishman; Juan P Zambrano; Alan W Heldman; Joshua M Hare
Journal: Circ Res Date: 2011-03-17 Impact factor: 17.367

6. Direct reprogramming of fibroblasts into functional cardiomyocytes by defined factors.

Authors: Masaki Ieda; Ji-Dong Fu; Paul Delgado-Olguin; Vasanth Vedantham; Yohei Hayashi; Benoit G Bruneau; Deepak Srivastava
Journal: Cell Date: 2010-08-06 Impact factor: 41.582

7. Rationale and design of the Transendocardial Injection of Autologous Human Cells (bone marrow or mesenchymal) in Chronic Ischemic Left Ventricular Dysfunction and Heart Failure Secondary to Myocardial Infarction (TAC-HFT) trial: A randomized, double-blind, placebo-controlled study of safety and efficacy.

Authors: Barry Trachtenberg; Darcy L Velazquez; Adam R Williams; Ian McNiece; Joel Fishman; Kim Nguyen; Didier Rouy; Peter Altman; Richard Schwarz; Adam Mendizabal; Behzad Oskouei; John Byrnes; Victor Soto; Melissa Tracy; Juan Pablo Zambrano; Alan W Heldman; Joshua M Hare
Journal: Am Heart J Date: 2011-03 Impact factor: 4.749

8. A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction.

Authors: Joshua M Hare; Jay H Traverse; Timothy D Henry; Nabil Dib; Robert K Strumpf; Steven P Schulman; Gary Gerstenblith; Anthony N DeMaria; Ali E Denktas; Roger S Gammon; James B Hermiller; Mark A Reisman; Gary L Schaer; Warren Sherman
Journal: J Am Coll Cardiol Date: 2009-12-08 Impact factor: 24.094

9. Rationale and design for TIME: A phase II, randomized, double-blind, placebo-controlled pilot trial evaluating the safety and effect of timing of administration of bone marrow mononuclear cells after acute myocardial infarction.

Authors: Jay H Traverse; Timothy D Henry; Douglas E Vaughan; Douglas E Vaughn; Stephen G Ellis; Carl J Pepine; James T Willerson; David X M Zhao; Linda B Piller; Marc S Penn; Barry J Byrne; Emerson C Perin; Adrian P Gee; Antonis K Hatzopoulos; David H McKenna; John R Forder; Doris A Taylor; Christopher R Cogle; Rachel E Olson; Beth C Jorgenson; Shelly L Sayre; Rachel W Vojvodic; David J Gordon; Sonia I Skarlatos; Lemuel A Moye'; Robert D Simari
Journal: Am Heart J Date: 2009-07-23 Impact factor: 4.749

Bone marrow therapy for myocardial infarction.

1. Autologous mesenchymal stem cells mobilize cKit+ and CD133+ bone marrow progenitor cells and improve regional function in hibernating myocardium.

2. Bone marrow mesenchymal stem cells stimulate cardiac stem cell proliferation and differentiation.

3. Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction.

Review 4. Mesenchymal stem cells: biology, pathophysiology, translational findings, and therapeutic implications for cardiac disease.

5. Intramyocardial stem cell injection in patients with ischemic cardiomyopathy: functional recovery and reverse remodeling.

6. Direct reprogramming of fibroblasts into functional cardiomyocytes by defined factors.

8. A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction.

9. Rationale and design for TIME: A phase II, randomized, double-blind, placebo-controlled pilot trial evaluating the safety and effect of timing of administration of bone marrow mononuclear cells after acute myocardial infarction.

Review 10. Adult bone marrow-derived cells for cardiac repair: a systematic review and meta-analysis.

Review 1. Cell-based therapy for prevention and reversal of myocardial remodeling.

Review 2. Key developments in stem cell therapy in cardiology.

3. Mesenchymal stem cell transplantation improves regional cardiac remodeling following ovine infarction.